Literature DB >> 31391803

Treatment De-Escalation in Patients With Inflammatory Bowel Disease.

Amanda Israel1, Katia El Jurdi1, David T Rubin1.   

Abstract

Inflammatory bowel disease follows a relapsing and remitting course that can be augmented with the use of various pharmacologic therapies. Treatments used to induce or maintain remission may not be required indefinitely. The associated side-effect profile, adverse events, and costs are additional motivators for providers to treat patients with the lowest dose of effective medications. De-escalation of therapy, whether dose reduction or drug discontinuation, must be carefully considered on an individual patient basis. The steps for de-escalation include confirmation of deep remission, development of a maintenance strategy, discussion of the rescue threshold and treatment options in the event of relapse, and appropriate discussion with the patient of this plan.

Entities:  

Keywords:  De-escalation; inflammatory bowel disease; treat to target

Year:  2019        PMID: 31391803      PMCID: PMC6676361     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  27 in total

Review 1.  Monitoring in chronic disease: a rational approach.

Authors:  Paul Glasziou; Les Irwig; David Mant
Journal:  BMJ       Date:  2005-03-19

2.  Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?

Authors:  E Domènech; J Hinojosa; P Nos; E Garcia-Planella; E Cabré; I Bernal; M A Gassull
Journal:  Aliment Pharmacol Ther       Date:  2005-12       Impact factor: 8.171

3.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

4.  Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Authors:  Casper Steenholdt; Akbar Molazahi; Mark Andrew Ainsworth; Jørn Brynskov; Ole Østergaard Thomsen; Jakob Benedict Seidelin
Journal:  Scand J Gastroenterol       Date:  2012-03-01       Impact factor: 2.423

5.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

6.  Drug-induced pancreatitis: an update.

Authors:  Chirag D Trivedi; C S Pitchumoni
Journal:  J Clin Gastroenterol       Date:  2005-09       Impact factor: 3.062

7.  Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.

Authors:  Abderrahim Oussalah; Jean-Baptiste Chevaux; Renaud Fay; William J Sandborn; Marc-André Bigard; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2010-04-13       Impact factor: 10.864

8.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

9.  Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse.

Authors:  Xavier Treton; Yoram Bouhnik; Jean-Yves Mary; Jean-Frédéric Colombel; Bernard Duclos; Jean-Claude Soule; Eric Lerebours; Jacques Cosnes; Marc Lemann
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-04       Impact factor: 11.382

10.  Development of the Crohn's disease digestive damage score, the Lémann score.

Authors:  Benjamin Pariente; Jacques Cosnes; Silvio Danese; William J Sandborn; Maïté Lewin; Joel G Fletcher; Yehuda Chowers; Geert D'Haens; Brian G Feagan; Toshifumi Hibi; Daniel W Hommes; E Jan Irvine; Michael A Kamm; Edward V Loftus; Edouard Louis; Pierre Michetti; Pia Munkholm; Tom Oresland; Julian Panés; Laurent Peyrin-Biroulet; Walter Reinisch; Bruce E Sands; Juergen Schoelmerich; Stefan Schreiber; Herbert Tilg; Simon Travis; Gert van Assche; Maurizio Vecchi; Jean-Yves Mary; Jean-Frédéric Colombel; Marc Lémann
Journal:  Inflamm Bowel Dis       Date:  2010-11-28       Impact factor: 5.325

View more
  1 in total

1.  Restarting Biologic Agents After a Drug Holiday.

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.